ramelteon ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2355 196597-26-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ramelteon
  • rozerem
  • TAK-375
Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors. The activity of ramelteon at the MT1 and MT2 receptors is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle.
  • Molecular weight: 259.35
  • Formula: C16H21NO2
  • CLOGP: 2.48
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -4.20
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.44 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1.80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.05 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 22, 2005 FDA TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal dreams 131.06 16.93 45 5520 10471 63472986
Initial insomnia 124.33 16.93 38 5527 6119 63477338
Nightmare 118.09 16.93 49 5516 19145 63464312
Middle insomnia 104.69 16.93 40 5525 12603 63470854
Somnolence 74.87 16.93 85 5480 178600 63304857
Product dispensing error 69.12 16.93 28 5537 10277 63473180
Poor quality sleep 59.98 16.93 31 5534 19904 63463553
Altered state of consciousness 47.91 16.93 29 5536 25201 63458256
Hepatic function abnormal 46.77 16.93 33 5532 37109 63446348
Ovarian cancer recurrent 37.30 16.93 10 5555 1007 63482450
Hallucination 35.46 16.93 33 5532 54784 63428673
Restlessness 34.39 16.93 25 5540 29428 63454029
Somnambulism 33.56 16.93 14 5551 5529 63477928
Feeling abnormal 30.46 16.93 50 5515 148342 63335115
Intentional overdose 28.83 16.93 34 5531 74118 63409339
Galactorrhoea 26.86 16.93 11 5554 4144 63479313
Blood pressure decreased 25.58 16.93 30 5535 64992 63418465
Hypersomnia 24.97 16.93 17 5548 18038 63465419
Hangover 24.32 16.93 8 5557 1628 63481829
Drug eruption 24.01 16.93 20 5545 28674 63454783
Anxiety 21.39 16.93 54 5511 217487 63265970
Impulsive behaviour 20.59 16.93 7 5558 1576 63481881
Platelet count decreased 19.72 16.93 36 5529 116086 63367371
Hallucination, visual 19.44 16.93 15 5550 19283 63464174
Delirium 19.34 16.93 23 5542 50518 63432939
Anaemia 19.29 16.93 63 5502 293367 63190090
Product administered to patient of inappropriate age 18.93 16.93 8 5557 3260 63480197
Interstitial lung disease 18.65 16.93 25 5540 61883 63421574
Arthralgia 18.25 16.93 14 5551 569696 62913761
Palpitations 17.94 16.93 34 5531 112736 63370721
Pneumonia aspiration 17.14 16.93 18 5547 34522 63448935
Renal impairment 17.07 16.93 29 5536 88326 63395131

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Somnolence 70.33 17.95 75 3988 111041 34841827
Initial insomnia 64.63 17.95 21 4042 3103 34949765
Pneumonia aspiration 55.71 17.95 43 4020 41860 34911008
Hangover 52.53 17.95 14 4049 1037 34951831
Abnormal dreams 49.73 17.95 22 4041 7556 34945312
Middle insomnia 48.71 17.95 21 4042 6781 34946087
Nightmare 47.08 17.95 26 4037 14365 34938503
Interstitial lung disease 41.09 17.95 44 4019 65238 34887630
Hepatic function abnormal 39.23 17.95 36 4027 44327 34908541
Disseminated intravascular coagulation 34.81 17.95 25 4038 21791 34931077
Poor quality sleep 32.86 17.95 17 4046 8239 34944629
Delirium 31.89 17.95 32 4031 43959 34908909
Cerebral infarction 27.67 17.95 24 4039 27431 34925437
Upper respiratory tract inflammation 25.35 17.95 9 4054 1735 34951133
Restlessness 21.20 17.95 20 4043 25462 34927406
Altered state of consciousness 21.04 17.95 19 4044 22874 34929994
Renal impairment 20.24 17.95 38 4025 94475 34858393

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Initial insomnia 102.84 16.16 35 7976 6903 79729474
Hepatic function abnormal 82.10 16.16 64 7947 73043 79663334
Middle insomnia 80.58 16.16 37 7974 16032 79720345
Somnolence 80.38 16.16 109 7902 238872 79497505
Pneumonia aspiration 73.84 16.16 58 7953 66909 79669468
Poor quality sleep 62.90 16.16 35 7976 22687 79713690
Altered state of consciousness 61.79 16.16 44 7967 43778 79692599
Abnormal dreams 59.49 16.16 27 7984 11385 79724992
Hangover 53.40 16.16 16 7995 2096 79734281
Interstitial lung disease 53.25 16.16 61 7950 112539 79623838
Delirium 47.20 16.16 50 7961 84577 79651800
Restlessness 46.40 16.16 38 7973 46454 79689923
Nightmare 46.04 16.16 30 7981 25831 79710546
Disseminated intravascular coagulation 39.39 16.16 31 7980 35811 79700566
Femoral neck fracture 34.99 16.16 18 7993 9966 79726411
Cerebral infarction 32.86 16.16 31 7980 45645 79690732
Drug eruption 31.95 16.16 30 7981 43905 79692472
Renal impairment 30.63 16.16 56 7955 157727 79578650
Product administered to patient of inappropriate age 28.50 16.16 13 7998 5540 79730837
Hypersomnia 27.61 16.16 21 7990 23065 79713312
Marasmus 26.91 16.16 8 8003 1020 79735357
Upper respiratory tract inflammation 25.72 16.16 11 8000 4024 79732353
Arthralgia 25.25 16.16 13 7998 571790 79164587
Intentional overdose 24.99 16.16 41 7970 105919 79630458
Platelet count decreased 23.62 16.16 57 7954 194607 79541770
Anaemia 23.02 16.16 97 7914 444918 79291459
Blood pressure decreased 22.80 16.16 38 7973 99428 79636949
Gastroenteritis eosinophilic 20.51 16.16 5 8006 300 79736077
Hallucination 19.98 16.16 33 7978 85712 79650665
Spinal compression fracture 19.34 16.16 15 7996 16943 79719434
Stoma site hypergranulation 18.63 16.16 5 8006 440 79735937
Cardiac failure acute 17.89 16.16 15 7996 18914 79717463
Zinc deficiency 17.71 16.16 4 8007 172 79736205
Ileus 17.35 16.16 17 7994 26194 79710183
Decreased appetite 17.18 16.16 74 7937 342344 79394033
Respiratory failure 16.85 16.16 48 7963 180863 79555514
Feeling abnormal 16.57 16.16 44 7967 159155 79577222
Somnambulism 16.34 16.16 9 8002 5712 79730665

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CH02 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Melatonin receptor agonists
FDA MoA N0000000250 Melatonin Receptor Agonists
FDA EPC N0000175743 Melatonin Receptor Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Initial insomnia indication 59050008
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Depressive disorder contraindication 35489007
Hepatic failure contraindication 59927004
Sleep apnea contraindication 73430006 DOID:0050847
Disease of liver contraindication 235856003 DOID:409
Hyperprolactinemia contraindication 237662005 DOID:12700
Sleep automatism contraindication 247962006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.14 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Melatonin receptor type 1A GPCR AGONIST Ki 10.90 WOMBAT-PK CHEMBL
Melatonin receptor type 1B GPCR AGONIST Ki 10.39 WOMBAT-PK CHEMBL

External reference:

IDSource
4024923 VUID
N0000171613 NUI
D02689 KEGG_DRUG
4024923 VANDF
C1565316 UMLSCUI
CHEBI:109549 CHEBI
JEV PDB_CHEM_ID
CHEMBL1218 ChEMBL_ID
DB00980 DRUGBANK_ID
C495910 MESH_SUPPLEMENTAL_RECORD_UI
208902 PUBCHEM_CID
1356 IUPHAR_LIGAND_ID
8447 INN_ID
901AS54I69 UNII
596205 RXNORM
20324 MMSL
320752 MMSL
70325 MMSL
d05578 MMSL
010947 NDDF
419588002 SNOMEDCT_US
419878007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 0591-2191 TABLET 8 mg ORAL ANDA 27 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 0591-2191 TABLET 8 mg ORAL ANDA 27 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 0832-1250 TABLET, FILM COATED 8 mg ORAL ANDA 30 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 0832-1250 TABLET, FILM COATED 8 mg ORAL ANDA 30 sections
Rozerem HUMAN PRESCRIPTION DRUG LABEL 1 21695-183 TABLET, FILM COATED 8 mg ORAL NDA 30 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 42291-776 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 42571-375 TABLET 8 mg ORAL ANDA 25 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 43598-741 TABLET 8 mg ORAL ANDA 25 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 43598-741 TABLET 8 mg ORAL ANDA 25 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 50268-708 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 50268-708 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 50436-3980 TABLET, FILM COATED 8 mg ORAL ANDA 28 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 51407-375 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 51407-375 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 52817-235 TABLET, FILM COATED 8 mg ORAL ANDA 28 sections
Rozerem HUMAN PRESCRIPTION DRUG LABEL 1 54868-5649 TABLET, FILM COATED 8 mg ORAL NDA 18 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 55700-874 TABLET, FILM COATED 8 mg ORAL ANDA 28 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 55700-874 TABLET, FILM COATED 8 mg ORAL ANDA 28 sections
RAMELTEON Human Prescription Drug Label 1 59651-505 TABLET, FILM COATED 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 60687-692 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 63629-8264 TABLET 8 mg ORAL ANDA 28 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 63629-8264 TABLET 8 mg ORAL ANDA 28 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 63629-8531 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 63629-8531 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 63629-8531 TABLET 8 mg ORAL ANDA 26 sections
Rozerem HUMAN PRESCRIPTION DRUG LABEL 1 64764-805 TABLET, FILM COATED 8 mg ORAL NDA 27 sections
Rozerem HUMAN PRESCRIPTION DRUG LABEL 1 64764-805 TABLET, FILM COATED 8 mg ORAL NDA 27 sections
Rozerem HUMAN PRESCRIPTION DRUG LABEL 1 68151-4881 TABLET, FILM COATED 8 mg ORAL NDA 28 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 70010-028 TABLET 8 mg ORAL ANDA 26 sections
Ramelteon HUMAN PRESCRIPTION DRUG LABEL 1 70010-028 TABLET 8 mg ORAL ANDA 26 sections